Biotechnology Sector

In a groundbreaking study published in Adaptive Human Behavior and Physiology, researchers Li, J., Lee, P., and Rafiee, Y. explored a previously under-researched area of psychological development regarding parental age and its influence on offspring’s social preferences. The research specifically addressed whether individuals born to older parents exhibit weaker preferences for younger adult faces compared

The peer recovery coach program in the United States has become a focal point for examining innovative strategies tied to substance use recovery. In a new study spearheaded by researchers including Ibragimov, Giordano, and Amaresh, insights from qualitative assessments shed light on the effectiveness and implementation of these programs. The research, set to be published

In recent years, the field of medical reconstruction has witnessed a transformative revolution, particularly within the realm of mandibular surgery. The traditional approaches, which often yielded unsatisfactory results and involved protracted recovery periods, have gradually been supplanted by pioneering techniques that personalize reconstructive solutions. A recent study underscores the efficacy of in-house patient-specific solutions for

In a notable advance within pediatric genetics, a recent case report has brought to light a novel homozygous variant in the ACSL5 gene, which has been implicated in a rare yet severe condition known as Congenital Diarrhea and Enteropathy (CODE). This groundbreaking discovery emerges from meticulous research conducted by a team of dedicated scientists, including

In the world of animal behavior, few phenomena are as fascinating as the collective decision-making processes in fish shoals. New groundbreaking research conducted by Boussard et al. has shed light on how guppy shoals, specifically those selected for larger telencephalon sizes, exhibit a remarkably enhanced ability to make swift decisions when faced with the looming

In a groundbreaking development that stands to redefine the management of co-working spaces, researcher S. Ding has introduced a dynamic scheduling framework that leverages the power of multi-agent reinforcement learning. As the demand for flexible work environments rises, this innovative approach promises not only to enhance resource allocation but also to optimize user experiences effectively.

In an era where the intricacies of human existence are constantly explored, J.C. Cordova’s latest reflection, titled “Falling Into Life: a Reflection on ‘Back’ by Jane Kenyon,” draws profound insights from the poignant themes presented in Jane Kenyon’s poetry. This exploration delves deeply into the connections between literature and the human experience, shedding light on

In a significant development in the field of hematology, researchers have pinpointed critical prognostic factors for elderly patients suffering from large B-cell lymphoma (LBCL). This study, which highlights the relationship between low serum albumin levels and the specific B-cell subtypes as identified by the Hans algorithm, opens new avenues for personalized treatment strategies in patients

In an era where the digital landscape profoundly influences health care, a groundbreaking study is emerging on the horizon, promising to revolutionize the way rehabilitation and physical activity are conducted for older adults following total hip arthroplasty. The research, spearheaded by a team of specialists, explores the intersection of technology and elder care, aiming to

Recent advancements in our understanding of endometriosis have revealed significant insights into the mechanisms underlying this complex condition. New research by Zhuang, Lyu, Chen, and colleagues delves into the multifaceted roles of the bacterium Streptococcus agalactiae and the metabolite L-carnitine in the development of lesions and the process of angiogenesis. This study, published in the

As we navigate through the lingering effects of the COVID-19 pandemic, one of the most alarming outcomes is the increasing prevalence of diabetes among those who have been infected with the virus. This condition, often referred to as post-COVID-19 diabetes, has emerged as a significant public health concern. Researchers have begun to peel back the

The global pandemic triggered by COVID-19 has not only altered health policies but has also cast a long shadow over healthcare accessibility, particularly in countries like Nigeria. A new study examines the interplay between mobility-restricting policies implemented during the pandemic and the public’s perception of COVID-19 risks, highlighting their profound impact on unmet medical needs

In a groundbreaking study published in BMC Genomics, researchers Liu, W., Li, J., and Fan, Z. examine the complete chloroplast genomes of various species within the genus Lygodium, exploring the intricate phylogenetic relationships among Lygodiaceae species found throughout China. This comprehensive analysis not only sheds light on the evolutionary trajectories of these fern species but

In the rapidly evolving landscape of robotics, researchers are making strides in creating more adaptable and autonomous systems. One such groundbreaking development comes from a collaborative effort led by L. Robinson, M. Gadd, and P. Newman, whose research titled “Robot-relay: building-wide, calibration-less visual servoing with learned sensor handover networks” aims to redefine how robots interact

In a transformative shift toward sustainable energy solutions, the pursuit of hydrogen as a fuel source for heavy-duty engines has garnered immense interest. This expansive investigation, spearheaded by researchers including Kappacher, Kapeller, and Christoforetti, delves into the complexities surrounding combustion phenomena in hydrogen engines operating under specific conditions. The implications of this research extend far

In an era characterized by relentless advancements in aerospace technology, the evolution of hypersonic flight represents a paramount frontier. A recent study by Soni et al. shines exceptional light on this field, focusing specifically on the numerical simulation and analysis of scramjet inlets under off-design conditions within hypersonic flows. The findings have significant implications not

Mild Cognitive Impairment (MCI) represents a transitional phase between normal cognitive aging and more severe forms of cognitive decline, including Alzheimer’s disease. As the global population ages, the prevalence of MCI has become a significant concern for healthcare systems, prompting extensive research into interventional strategies to mitigate its effects. Recent scholarly work conducted by M.A.

The rise of social media has transformed how we communicate and express our emotions, creating an expansive digital landscape infused with sentiment-laden content. To navigate this intricate world, researchers have increasingly turned to advanced computational methods for analyzing large volumes of social media texts. One of the latest contributions in this sphere is a groundbreaking

In a groundbreaking study, researchers have turned their focus toward evaluating the clinical risk factors for osteoporotic fractures among women in Armenia who are aged 40 and above. Osteoporosis is a silent disease, often sneaking up on its victims without any symptoms until a fracture occurs. The research highlights not just the prevalence of this

Kaposi sarcoma, once primarily associated with HIV infection, has gained attention in recent medical literature for its presentation in immunocompetent individuals, particularly young men. In a groundbreaking study led by Goorman et al., researchers delve into the nuances of Kaposi sarcoma subtypes, shining a light on cases that deviate from the classical narrative surrounding this

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff is driving deals. The post What does 2026 hold for the biotech industry?  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.

Today, we're thrilled to have Tim Opler, a leading voice in biotech investment banking. The post Top 5 trends that will drive biopharma in the next decade with Tim Opler appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospects of a molecule tipped to generate blockbuster sales.

Bristol Myers Squibb added a big name to its executive roster with the appointment of Harald Hampel, M.D., Ph.D. as its new SVP and worldwide head of medical affairs, neuroscience. Hampel comes to BMS after six years at Eisai, where he was responsible for the global Alzheimer’s disease strategy that eventually birthed Alzheimer’s disease treatment Leqembi (lecanemab).

Hoth Therapeutics has shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another milestone for a candidate designed to complement cancer therapies.

In a reminder of the money still available for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in series D funds to bankroll phase 2 studies of its oral GLP-1 receptor agonist.

Corcept Therapeutics’ relacorilant has improved overall survival in a phase 3 ovarian cancer study, building on interim data published last year to give the biotech momentum heading into an FDA approval ruling.

Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic.

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease and complete response to support accelerated approval of drugs to treat multiple myeloma.

Here are some of the diseases that scientists aim to tackle using CRISPR technology, testing its possibilities and limits as a medical tool. The post Could CRISPR really cure these diseases?  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality.

Cancer imaging company Kuva Labs is expanding its scope via the acquisition of solid tumor biotech Lisata Therapeutics.

Only four months after IO Biotech decided to halve its head count, the Danish biotech is already considering whether it must resort to further layoffs.

AI-powered drug developer Insilico Medicine is set for a $10 million upfront payment from a fresh-faced Chinese biotech for half of the rights to a brain-penetrant NLRP3 inhibitor.

For the second year in a row, flashes of pink cut through the sea of navy, gray and black that flooded San Francisco’s Union Square during the J.P. Morgan Annual Healthcare Conference. The color—largely worn by female attendees—stood out on streets that have been historically dominated by men during the event.

Riding a regulatory win for its base editing candidate, Beam Therapeutics is “putting all of our eggs” in the in vivo delivery basket, CEO John Evans said.

Find out whether we are closing in on a cure for hepatitis B - a virus affecting the liver that can cause acute and chronic disease. The post Hepatitis B: Are we edging closer to a cure? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Two former executives at Spero Therapeutics have agreed to settle with the Securities and Exchange Commission for allegedly misleading investors about the efficacy of the biotech’s lead antibiotic candidate, with a total fine of $187,500.

Tanabe Pharma America’s small molecule designed to boost melanin production has hit the main goal of a phase 3 trial for patients with rare hereditary disorders that cause extreme sensitivity to sunlight.

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the pharma’s vaccine programs, with hundreds of millions of dollars in milestones tied to the deal.

Explore how leadership in biotech drives success through a milestone approach, aligning teams and culture from science to scale. The post From science to scale: building biotech companies via milestone leadership appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Boundless Bio has finally given up on its hopes of finding redemption for two solid tumor drugs that had both come up short in the clinic by packaging them up as a combination treatment.

Adding Merck & Co. and Moderna’s vaccine candidate to Keytruda has continued to cut the risk of cancer recurrence or death across five years of follow-up, boosting the companies’ prospects as they close in on phase 3 data.

GSK is paying $2.2 billion to buy Rapt Therapeutics and its anti-immunoglobulin E (IgE) antibody to protect against food allergy reactions.

Delve into the increasingly dynamic landscape of ALS treatment development with ten companies advancing candidates in 2026. The post Curing ALS? Ten companies developing new treatments in 2026  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

The therapy in question, dubbed C-CAR031, is based on AstraZeneca’s own GPC3-targeting CAR-T.

This year, JPM 2026 took place again in San Francisco. Let’s look at predictions and trends forecast for 2026, according to attendees at JPM. The post JPM 2026: what’s the outlook like this year?  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

The post Labiotech’s 15 biopharma companies to watch in 2026 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

iRegene’s NouvNeu001 earns dual FTD/RMAT status, a first for iPSC therapies. Strong Phase I data in PD validates its scalable chemical induction platform.

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent cliff. The post The AbbVie strategy, a company at an inflection point   appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Explore some of the top biotech companies in the Netherlands, which has established itself as a burgeoning biotech and life sciences hub. The post Seven biotech companies to know in the Netherlands  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Here is a list of 14 biotech podcasts to keep you up to date with the latest advances in the biotechnology industry. The post 14 biotech podcasts to tune into in 2026  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in December 2025. The post The biggest biotech funding rounds in December 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

Stegeman says decentralized trial models improve access, diversity and patient retention

Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. With the rise of international trade and the... Source

The Complex World of Biologic Drugs: Navigating Patent Applications As a biotech professional, you're likely no stranger to the intricacies of developing life-saving treatments. But when it comes to biologic drugs, the process can be particularly chall... Source

Unlocking the Power of Combination Therapies: Strategies for Successful Patenting As a pharmaceutical professional, you know that combination therapies have revolutionized the treatment of complex diseases. By pairing two or more active ingredients, yo... Source

The Secret to Setting the Right Price for Your Generic Medications As a generic drug manufacturer, you're constantly looking for ways to stay ahead of the competition and bring affordable medications to market. But have you ever wondered how to set the... Source

Unlocking Efficiency in the Generic Drug Supply Chain As the pharmaceutical industry continues to evolve, the generic drug supply chain has become a critical component of ensuring timely and affordable access to life-saving medications. However, naviga... Source

Breaking News: FDA Updates - What Do the Latest Changes Mean for Generic Drug Approval? As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic drug approval. Re... Source

Breaking Down Barriers: Navigating Regulatory Challenges in Latin America's Generic Drug Market As the demand for affordable generic medications continues to grow, Latin America has emerged as a critical region for pharmaceutical companies looking to e... Source

The Future of Affordable Healthcare: Can Biosimilars Deliver? As healthcare professionals, we're constantly on the lookout for innovative solutions to improve patient outcomes while reducing costs. One promising approach is the use of biosimilars – bio... Source

Ensuring the Highest Quality in Generic Medications: A Crucial Step in Healthcare As the global demand for affordable healthcare continues to rise, generic medications have become a vital lifeline for millions of people worldwide. However, with the inc... Source

The Unseen Heroes of Generic Medicines: The Crucial Role of Quality Assurance As we navigate the complex world of pharmaceuticals, it's easy to overlook the unsung heroes behind the scenes. But today, I want to shine a spotlight on the Quality Assuranc... Source

Can Lurbinectedin Treat Ovarian Cancer? A Comprehensive Review Ovarian cancer is a devastating disease that affects thousands... https://www.Drugchatter.com/chat/25460/can-lurbinectedin-treat-ovarian-cancer/ Source

Unlocking the Potential of Biosimilars: Navigating Regulatory Considerations for Clinical Efficacy Trials As the pharmaceutical industry continues to evolve, biosimilars have emerged as a game-changer in the quest for affordable and accessible treatmen... Source

Unlock the Secrets of Drug Patent Searching: A Beginner's Guide As a professional in the pharmaceutical industry, staying ahead of the curve is crucial. One of the most critical aspects of this is understanding the world of drug patents. But have you e... Source

Unlocking the Path to Generic Medication Approval: A Step-by-Step Guide As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic medication approval. With the eve... Source

The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, one question on everyone's mind is: how can we make the most of this opportunity? One strategy that's gaining traction is biosimilar-to-biosimilar s... Source

The Hidden Factors Behind FDA-Approved Drugs' Patent Challenges As a healthcare professional or a pharmaceutical industry expert, you're likely no stranger to the complex world of drug patents. But have you ever wondered what sets some FDA-approved dru... Source

Breaking Down Barriers: The Power of Partnerships in Generic Drug Development As the pharmaceutical industry continues to evolve, one thing is clear: collaboration is key. In the world of generic drug development, partnerships are playing an increasing... Source

Does Fish Oil Interact with Vascepa? A Comprehensive Guide As the world becomes increasingly aware of the importance of... https://www.Drugchatter.com/chat/45752/does-fish-oil-interact-with-vascepa/ Source

The Art of Timing: Mastering Generic Drug Development Timelines As a seasoned professional in the pharmaceutical industry, you know that navigating the complex landscape of generic drug development can be a daunting task. One of the most critical facto... Source

The Impact of Lipitor on White Wine: A Comprehensive Guide As a popular cholesterol-lowering medication, Lipitor (atorvastatin)... https://www.Drugchatter.com/chat/37341/how-does-lipitor-affect-white-wine/ Source

With significant growth in activities globally, our /local page has strained to keep up and simply is not a great...